Close Menu

MIT

The partners will use ReviveMed's AI-driven platform to better understand mechanisms of immunotherapy response and resistance in cancer patients.

The grant recipients will receive up to $5 million each and are led by scientists at institutions including Harvard Medical School and the Cleveland Clinic.

Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.

Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.